PrecisionBiome provides an end‑to‑end platform that delivers ultra‑high‑resolution gut microbiome sequencing combined with AI‑driven predictive modeling to generate personalized disease‑risk assessments and therapeutic recommendations. The service includes GMP‑compliant manufacturing of standardized microbiome therapeutics and a reproducible workflow for sample collection, data analysis, and intervention delivery, targeting clinics, performance centers, and research institutions.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of individuals suffer from chronic conditions that are difficult to manage because current microbiome diagnostics lack sufficient resolution and reproducibility, limiting clinicians’ ability to design effective, personalized interventions. Existing analysis pipelines provide low‑resolution data, making it hard to link gut microbial composition to specific health outcomes. Consequently, healthcare providers and performance programs struggle to implement scalable, evidence‑based microbiome therapies.
Solution
PrecisionBiome delivers an end‑to‑end European platform that transforms gut microbiome data into actionable, hyper‑personalized health interventions. The platform combines ultra‑high‑resolution microbial profiling with a proprietary AI engine trained on 100 k clinical cases and 70 M data points to generate predictive models of disease risk and therapeutic response. Clinical‑grade GMP manufacturing facilities produce standardized, reproducible microbiome‑based therapeutics that can be integrated into existing care pathways. Partners receive a repeatable workflow—from sample collection and high‑fidelity analytics to intervention modeling and manufacturing—enabling consistent outcome tracking and patient retention. All components are built on European scientific rigor and quality standards, ensuring data integrity, regulatory compliance, and long‑term scalability.
Target Audience
Primary customers are clinical clinics, performance and longevity centers, and research institutions that require a reliable, high‑resolution microbiome analysis pipeline and scalable therapeutic manufacturing to improve patient outcomes.
Features
- 400× higher resolution microbial sequencing compared with conventional platforms, delivering stable and comparable taxonomic profiles
- Proprietary AI analytics platform that leverages 100 k clinical facts and 70 M datapoints to predict disease trajectories and personalize interventions
- Clinical‑grade GMP manufacturing in a European pharmacy, providing batch‑consistent, regulatory‑compliant microbiome therapeutics
- Fully integrated end‑to‑end workflow: sample intake, high‑fidelity data generation, AI‑driven modeling, and on‑demand therapeutic production
- Robust data management pipeline ensuring reproducibility, traceability, and compliance with EU health data regulations
- Scalable partnership model for clinics, performance centers, and longevity programs seeking repeatable microbiome workflows
- Research collaboration support with high‑resolution datasets and intervention modeling tools for scientific studies